PTC Therapeutics Inc (PTCT)
42.89
+0.93
(+2.22%)
USD |
NASDAQ |
Nov 21, 16:00
41.91
-0.98
(-2.28%)
Pre-Market: 08:58
PTC Therapeutics Enterprise Value: 2.580B for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 2.580B |
| November 20, 2024 | 2.508B |
| November 19, 2024 | 2.307B |
| November 18, 2024 | 2.297B |
| November 15, 2024 | 2.297B |
| November 14, 2024 | 2.540B |
| November 13, 2024 | 2.668B |
| November 12, 2024 | 2.713B |
| November 11, 2024 | 2.732B |
| November 08, 2024 | 2.687B |
| November 07, 2024 | 2.585B |
| November 06, 2024 | 2.602B |
| November 05, 2024 | 2.424B |
| November 04, 2024 | 2.380B |
| November 01, 2024 | 2.386B |
| October 31, 2024 | 2.344B |
| October 30, 2024 | 2.401B |
| October 29, 2024 | 2.542B |
| October 28, 2024 | 2.387B |
| October 25, 2024 | 2.408B |
| October 24, 2024 | 2.458B |
| October 23, 2024 | 2.541B |
| October 22, 2024 | 2.298B |
| October 21, 2024 | 2.230B |
| October 18, 2024 | 2.281B |
| Date | Value |
|---|---|
| October 17, 2024 | 2.120B |
| October 16, 2024 | 2.096B |
| October 15, 2024 | 2.162B |
| October 14, 2024 | 2.284B |
| October 11, 2024 | 2.273B |
| October 10, 2024 | 2.234B |
| October 09, 2024 | 2.345B |
| October 08, 2024 | 2.409B |
| October 07, 2024 | 1.964B |
| October 04, 2024 | 1.973B |
| October 03, 2024 | 1.994B |
| October 02, 2024 | 2.075B |
| October 01, 2024 | 2.046B |
| September 30, 2024 | 2.127B |
| September 27, 2024 | 2.081B |
| September 26, 2024 | 2.088B |
| September 25, 2024 | 2.010B |
| September 24, 2024 | 2.001B |
| September 23, 2024 | 2.018B |
| September 20, 2024 | 2.010B |
| September 19, 2024 | 1.973B |
| September 18, 2024 | 1.921B |
| September 17, 2024 | 1.889B |
| September 16, 2024 | 1.789B |
| September 13, 2024 | 1.806B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.292B
Minimum
Apr 18 2024
4.670B
Maximum
May 22 2023
2.846B
Average
2.870B
Median
Nov 23 2022
Enterprise Value Benchmarks
| ClearPoint Neuro Inc | 284.34M |
| Pfizer Inc | 199.35B |
| Vertex Pharmaceuticals Inc | 109.46B |
| BridgeBio Pharma Inc | 5.857B |
| Cassava Sciences Inc | 1.399B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -106.65M |
| Revenue (Quarterly) | 196.79M |
| Total Expenses (Quarterly) | 248.75M |
| EPS Diluted (Quarterly) | -1.39 |
| Gross Profit Margin (Quarterly) | 94.49% |
| Profit Margin (Quarterly) | -54.20% |
| Earnings Yield | -13.85% |
| Normalized Earnings Yield | -9.495 |